JOP20240212A1 - بولي ببتيدات اندماج SIRPα ذات مجالات Fc معدلّة - Google Patents

بولي ببتيدات اندماج SIRPα ذات مجالات Fc معدلّة

Info

Publication number
JOP20240212A1
JOP20240212A1 JOJO/P/2024/0212A JOP20240212A JOP20240212A1 JO P20240212 A1 JOP20240212 A1 JO P20240212A1 JO P20240212 A JOP20240212 A JO P20240212A JO P20240212 A1 JOP20240212 A1 JO P20240212A1
Authority
JO
Jordan
Prior art keywords
domains
modified
sirpα
fusion polypeptides
sirpα fusion
Prior art date
Application number
JOJO/P/2024/0212A
Other languages
Arabic (ar)
English (en)
Inventor
Jens-Peter Volkmer
Original Assignee
Bitterroot Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitterroot Bio Inc filed Critical Bitterroot Bio Inc
Publication of JOP20240212A1 publication Critical patent/JOP20240212A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JOJO/P/2024/0212A 2022-03-24 2024-09-29 بولي ببتيدات اندماج SIRPα ذات مجالات Fc معدلّة JOP20240212A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323417P 2022-03-24 2022-03-24
PCT/US2023/064886 WO2023183892A1 (en) 2022-03-24 2023-03-23 Sirp-alpha fusion polypeptides with modified fc domains

Publications (1)

Publication Number Publication Date
JOP20240212A1 true JOP20240212A1 (ar) 2024-09-29

Family

ID=86054071

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0212A JOP20240212A1 (ar) 2022-03-24 2024-09-29 بولي ببتيدات اندماج SIRPα ذات مجالات Fc معدلّة

Country Status (13)

Country Link
US (1) US20230365648A1 (https=)
EP (1) EP4499837A1 (https=)
JP (1) JP2025510774A (https=)
KR (1) KR20240162572A (https=)
CN (1) CN119546769A (https=)
AU (1) AU2023240361A1 (https=)
CA (1) CA3246192A1 (https=)
CL (1) CL2024002849A1 (https=)
CO (1) CO2024013909A2 (https=)
IL (1) IL315706A (https=)
JO (1) JOP20240212A1 (https=)
MX (1) MX2024011528A (https=)
WO (1) WO2023183892A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
US10011660B2 (en) * 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020263830A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Also Published As

Publication number Publication date
CO2024013909A2 (es) 2024-10-31
AU2023240361A1 (en) 2024-10-03
CL2024002849A1 (es) 2025-05-23
KR20240162572A (ko) 2024-11-15
CA3246192A1 (en) 2023-09-28
WO2023183892A1 (en) 2023-09-28
IL315706A (en) 2024-11-01
EP4499837A1 (en) 2025-02-05
MX2024011528A (es) 2024-12-06
JP2025510774A (ja) 2025-04-15
US20230365648A1 (en) 2023-11-16
CN119546769A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
CY1116952T1 (el) Ειδικες και υψηλης συγγενειας δεσμευομενες πρωτεϊνες που περιλαμβανουν τροποποιημενες περιοχες sh3 κινασης fyn
DK1641818T3 (da) Polypeptider der har bindingsaffinitet for HER2
MX2020007882A (es) Variantes fc con unión mejorada a fcrn y semivida prolongada.
TW200732472A (en) Method for the recombinant expression of a polypeptide
DE60330767D1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
EA200802396A1 (ru) УЛУЧШЕННЫЕ ДИМЕРЫ sgp130Fc
DE60203996D1 (de) Concatamere immunadhäsion
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
ES2671493T3 (es) Tratamiento con multiproteasa para el dolor crónico
MX386014B (es) Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
UA97628C2 (ru) Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе
JOP20240283A1 (ar) تركيبة منظف الشعر وفروة الرأس لإزالة السموم، طرق استخدامها واستخداماتها
SE0400274D0 (sv) New polypeptide
WO2022256498A9 (en) Msln targeting trispecific proteins and methods of use
CR20230015A (es) Fusiones heterodiméricas de relaxina y usos de las mismas
JP2020517260A5 (https=)
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
EA201892554A1 (ru) Мутант cd200 и его применения
MX2025000139A (es) Composicion limpiadora del cabello, metodos y usos de la misma
BR112022005426A2 (pt) Polipeptídeos de fusão dap10/dap12
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
MX2023009737A (es) Proteínas de fusion y constructos de acidos nucleicos.
BR112022026248A2 (pt) Conjugados de citocinas